跳至主要内容
临床试验/TCTR20200319003
TCTR20200319003Enrolling By Invitation3 期

Cut off value of noninvasive biomarkers and liver biopsy for staging liver fibrosis in chronic hepatitis patients

Srinagarind hospital Khon Kaen University0 个研究点目标入组 640 人开始时间: 2020年3月19日最近更新:
适应症

试验速览

阶段
3 期
状态
Enrolling By Invitation
发起方
入组人数
640

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • Description of subjects and main criteria for inclusion•Patients age 18-65 in the Srinagarind Hospital between years 2016-2018 and receive a diagnosis viral hepatitis B or C infection or non-alcoholic steatohepatitis (NASH) one only.
  • •ECOG performance status 0-1
  • •Patients must not treat with Peginterferon alfa (type 2a / 2b) in combination with Ribavirin before.
  • •Stop drinking alcohol more than six months.
  • •Child-Pugh score <= 6
  • •If cancer patients must undergo treatment to cure (curative aim) and disease-free period exceeding six months.
  • •Volunteers participated in the research.

排除标准

  • Description of main exclusion criteria•Patients with HIV co-infection.
  • •Patients with contraindications to liver biopsy: patients do not cooperate, patients with risk bleeding cannot be solved by providing blood components (INR> 1.5 platelet <80,000). , Patients with skin infections in the ribs, Patients with obstructive jaundice, Patients with ascites, Patients suspected liver nodules.
  • •Patients with uncontrolled underlying diseases, such as heart failure, renal failure, diabetes, hyper or hypothyroidism, hypertension, ischemic heart diseases, COPD, major depressive disorder.
  • •Patients do not stop antiplatelet at least 10 days.
  • •Pregnancy.
  • •Organ transplant.
  • •Patients during chemotherapy.
  • •Patients with acute hemolysis or extra hepatic cholestasis.
  • •Patients with chronic hemolysis or Gilbert's syndrome.

研究者

发起方
Srinagarind hospital Khon Kaen University

相似试验